Page 290 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPTEr 18 Regulatory Immune Cells 271

34
stimulatory molecules, either as monotherapies or in combina- 8. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells
tion, may help boost efficacy while reducing adverse events. 34 in the human immune system. Nat Rev Immunol 2010;10:490–500.
Conversely, in cases when tolerance should be reinforced 9. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage.
(autoimmunity, transplantation, allergy, fetomaternal tolerance) Nat Immunol 2007;8:457–62.
molecules that either mimic or enhance Tregs function and 10. Kitagawa Y, Ohkura N, Sakaguchi S. Epigenetic control of thymic
Treg-cell development. Eur J Immunol 2015;45:11–16.
survival are under investigation. In the former case, CTLA-4-Ig 11. Bollrath J, Powrie FM. Controlling the frontier: regulatory T-cells and
(abatacept; Orencia, Bristol-Myers Squibb, N.Y.), a solubilized intestinal homeostasis. Semin Immunol 2013;25:352–7.
version of CTLA-4 that, in part, mimics the effect of Tregs on 12. Lin X, Chen M, Liu Y, et al. Advances in distinguishing natural from
APCs by blocking their expression of B7.1 and B7.2, is currently induced Foxp3(+) regulatory T cells. Int J Clin Exp Pathol 2013;6:116–23.
being used for the treatment of, for example, RA. In addition, 13. Bayer AL, Pugliese A, Malek TR. The IL-2/IL-2R system: from basic
cellular therapy, by infusion of ex vivo or manipulated expanded science to therapeutic applications to enhance immune regulation.
Tregs, is in small-scale use in patients with GvHD after hema- Immunol Res 2013;57:197–209.
17
topoietic stem cell transplantation, and early trials of Treg 14. Wing JB, Sakaguchi S. Multiple Treg suppressive modules and their
transfer in recent-onset type 1 diabetes are underway. Further adaptability. Front Immunol 2012;3:178.
to this, transfer of Tr1 cells in patients with Crohn disease is 15. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid
tissues. Nat Immunol 2013;14:1007–13.
17
also under investigation. Cell-based therapies are, indeed, a 16. Walker LSK. Treg and CTLA-4: two intertwining pathways to immune
promising strategy for managing various immunological diseases tolerance. J Autoimmun 2013;45:49–57.
and immune responses; however, several challenges still remain, 17. Gregori S, Passerini L, Roncarolo MG. Clinical outlook for type-1 and
particularly those relating to the functional stability of ex FOXP3(+) T regulatory cell-based therapy. Front Immunol 2015;6:593.
vivo–expanded or –induced Tregs. 2 18. Battaglia M, Gregori S, Bacchetta R, et al. Tr1 cells: from discovery to
their clinical application. Semin Immunol 2006;18:120–7.
19. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune
ON THE HOrIZON homeostasis and suppression. Toxicol Pathol 2012;40:186–204.
20. Weiner HL, da Cunha AP, Quintana F, et al. Oral tolerance. Immunol Rev
• It is clear that regulatory T cells (Tregs) in different sites have phenotypic
differences, a greater understanding of Treg heterogeneity is critical 2011;241:241–59.
to clarification of their role in human autoimmunity. 21. Kim HJ, Cantor H. Regulation of self-tolerance by Qa-1-restricted
• Specific targeting of tumor-resident Tregs without depletion of peripheral CD8(+) regulatory T cells. Semin Immunol 2011;23:446–52.
Tregs is critical to enhancing antitumor therapy while avoiding adverse 22. Ligocki AJ, Niederkorn JY. Advances on non-CD4 + Foxp3+ T regulatory
events. cells: CD8+, type 1, and double negative T regulatory cells in organ
• Expansion and control of Treg subsets, such as T-follicular regulatory transplantation. Transplantation 2015;99:1553–9.
(Tfr) or muscle-resident Tregs, may be critical to fine control of specific 23. Hayday A, Tigelaar R. Immunoregulation in the tissues by gamma/delta T
immunological disorders. cells. Nat Rev Immunol 2003;3:233–42.
24. Rossjohn J, Pellicci DG, Patel O, et al. Recognition of CD1d-restricted
antigens by natural killer T cells. Nat Rev Immunol 2012;12:845–57.
Please check your eBook at https://expertconsult.inkling.com/ 25. Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function.
Immunity 2015;42:607–12.
for self-assessment questions. See inside cover for registration 26. Kumar V, Patel S, Tcyganov E, et al. The nature of myeloid-derived
details. suppressor cells in the tumor microenvironment. Trends Immunol
2016;37:208–20.
REFERENCES 27. Kim SJ, Diamond B. Modulation of tolerogenic dendritic cells and
autoimmunity. Semin Cell Dev Biol 2015;41:49–58.
1. Klein L, Kyewski B, Allen PM, et al. Positive and negative selection of the 28. Grant CR, Liberal R, Mieli-Vergani G, et al. Regulatory T-cells in
T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol autoimmune diseases: challenges, controversies and—yet—unanswered
2014;14:377–91. questions. Autoimmun Rev 2015;14:105–16.
2. Bluestone JA, Trotta E, Xu D. The therapeutic potential of regulatory T 29. Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role
cells for the treatment of autoimmune disease. Expert Opin Ther Targets of IL-10 and Tregs. J Clin Invest 2014;124:4678–80.
2015;1–13. 30. Soyka MB, Holzmann D, Akdis CA. Regulatory cells in allergen-specific
3. Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: immunotherapy. Immunotherapy 2012;4:389–96.
recommendations to simplify the nomenclature. Nat Immunol 31. Safinia N, Scotta C, Vaikunthanathan T, et al. Regulatory T cells: serious
2013;14:307–8. contenders in the promise for immunological tolerance in
4. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ transplantation. Front Immunol 2015;6:438.
regulatory T cells: more of the same or a division of labor? Immunity 32. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy.
2009;30:626–35. Curr Opin Immunol 2014;27:1–7.
5. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol 33. Berod L, Puttur F, Huehn J, et al. Tregs in infection and vaccinology:
Biol 2011;707:3–17. heroes or traitors? Microb Biotechnol 2012;5:260–9.
6. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on 34. Sharma P, Allison JP. The future of immune checkpoint therapy. Science
self-tolerance and autoimmunity. Nat Immunol 2010;11:7–13. 2015;348:56–61.
7. Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression 35. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab
by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory in advanced melanoma. N Engl J Med 2013;369:122–33.
conditions. Semin Immunol 2011;23:424–30.